These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11484961)

  • 1. Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.
    Vansteenkiste J; Gatzemeier U; Manegold C; Hanauske A; Weynants P; Bosquée L; Blatter J; Mansouri K; von Pawel J
    Ann Oncol; 2001 Jun; 12(6):835-40. PubMed ID: 11484961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
    De Marinis F; Migliorino MR; Paoluzzi L; Portalone L; Ariganello O; Cortesi E; Gamucci T; Gasperoni S; Cipri A; Martelli O; Nelli F;
    Lung Cancer; 2003 Mar; 39(3):331-8. PubMed ID: 12609572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
    ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
    Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.
    Biesma B; Smit EF; Postmus PE
    Lung Cancer; 1999 May; 24(2):115-21. PubMed ID: 10444062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.
    Rassmann I; Thödtmann R; Depenbrock H; Blatter J; Gatzemeier U; Rastetter J; Hanauske AR
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-75-S7-78. PubMed ID: 9194485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
    De Marinis F; Nelli F; Lombardo M; Ferraú F; Barbera S; Bertetto O; Barni S; Michetti G; Labianca R; Gridelli C
    Cancer; 2005 Feb; 103(4):772-9. PubMed ID: 15641037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
    Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W
    Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
    Hesketh PJ; Chansky K; Israel V; Grapski RT; Mekhail TM; Spiridonidis CH; Mills GM; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2007 May; 2(5):440-4. PubMed ID: 17473660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.
    Earle CC; Stewart DJ; Cormier Y; Evans WK; Gertler SZ; Mihalcioiu C; Walde PD
    Lung Cancer; 1998 Dec; 22(3):235-41. PubMed ID: 10048476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
    Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
    Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
    Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.